Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma - Wu, Jerry T.; Cheuk, Adam; Isanogle, Kristine; Robinson, Christina; Zhang, Xiaohu; Ceribelli, Michele; Beck, Erin; Shinn, Paul; Klumpp-Thomas, Carleen; Wilson, Kelli M.; McKnight, Crystal; Itkin, Zina; et al. (Cancers, 2023)
Keywords: Animal models; Antibodies; Biological products; Biotechnology industry; Cancer; Cell fusion; Chemotherapy; Clinical trials; Drug dosages; FDA approval; Fibroblast growth factor receptor 4; Fibroblast growth factor receptors; Fibroblasts; FOXO1 protein; Irinotecan; Kinases; Laboratory animals; Leukemia; Lymphocytes T; Medical research; Metastases; Pax3 protein; Pediatrics; Penicillin; Pharmaceutical industry; Phosphorylation; Protein-tyrosine kinase receptors; Proteins; R&D; Research & development; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; T cells; Toxicity; Tumors; Tyrosine; Vincristine; Xenografts; United States; Japan; United Kingdom--UK; United States--US; FGFR inhibitor; FGFR4; rhabdomyosarcoma; futibatinib; pediatric cancer